High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype
Search results
1679 results
-
-
Integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay) (DG26)
Evidence-based recommendations on integrated multiplex polymerase chain tests for identifying gastrointestinal pathogens in suspected gastroenteritis
-
Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast
-
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis
-
Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)
Evidence-based recommendations on lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care
-
Rapid tests for group A streptococcal infections in people with a sore throat (DG38)
Evidence-based recommendations on rapid tests for group A streptococcal (strep A) infections in people aged 5 and over with a sore throat
-
Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)
Evidence-based recommendations on viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems) to detect, manage and monitor haemostasis
-
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery
-
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)
Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
-
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
Evidence-based recommendations on the My5-FU assay for guiding dose adjustment for fluorouracil chemotherapy
-
PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease
In development [GID-DG10029] Expected publication date: 26 August 2020
-
High-sensitivity troponin for the early rule out of acute myocardial infarction
In development [GID-DG10035] Expected publication date: 26 August 2020
-
Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral for people with a change in bowel habit or abdominal pain
In development [GID-DG10036] Expected publication date: 12 May 2021
-
Testing strategies for Lynch syndrome in people with endometrial cancer: diagnostics consultation
We are listening to your views on this diagnostics guidance. Comments close 21 April 2020.
-
QAngio XA 3D/ QFR and CAAS vFFR imaging software for assessing the functional significance of coronary obstructions during invasive coronary angiography
In development [GID-DG10034] Expected publication date: 30 September 2020
-
Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test)
In development [GID-DG10028] Expected publication date: 22 April 2020
-
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke
In development [GID-DG10023] Expected publication date: 27 May 2020
-
Testing strategies for Lynch syndrome in people with endometrial cancer
In development [GID-DG10033] Expected publication date: 29 July 2020
-
COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)
The purpose of this guideline is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection.
-
COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.
-
COVID-19 rapid guideline: dialysis service delivery (NG160)
The purpose of this guideline is to maximise the safety of patients on dialysis, while protecting staff from infection. It will also enable dialysis services to make the best use of NHS resources and match the capacity of dialysis services to patient needs if these become limited because of the COVID-19 pandemic.
-
COVID-19 rapid guideline: delivery of radiotherapy (NG162)
The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.
-
COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)
The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources.
-
COVID-19 rapid guideline: severe asthma (NG166)
The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.
-
COVID-19 rapid guideline: critical care in adults (NG159)
The purpose of this guideline is to maximise the safety of patients who need critical care during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.
-
COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)
The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic. It will also enable services to make the best use of NHS resources. For general advice on managing COVID-19 symptoms, see the NICE COVID-19 rapid guideline on managing symptoms (including at the end of life) in the community .
-
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for transplantation to patient needs if services become limited because of the COVID-19 pandemic.
-
Alcohol-use disorders: diagnosis and management of physical complications (CG100)
This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.
-
Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal septicaemia (blood poisoning) in babies, children and young people under 16. It aims to reduce deaths and disability by promoting early recognition of symptoms and timely effective management.
-
Delirium: prevention, diagnosis and management (CG103)
This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.
-
Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)
This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.
-
Generalised anxiety disorder and panic disorder in adults: management (CG113)
This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.
-
Food allergy in under 19s: assessment and diagnosis (CG116)
This guideline covers assessing and managing food allergy in children and young people under 19. It aims to improve symptoms such as faltering growth and eczema by offering advice on how to identify food allergy and when to refer to secondary or specialist care.
-
Bedwetting in under 19s (CG111)
This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.
-
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancers in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition when this cannot be found.
-
Barrett's oesophagus: ablative therapy (CG106)
This guideline covers endoscopy treatments for people aged 18 and over with Barrett’s oesophagus and high-grade dysplasia or intramucosal cancer. It offers advice on which types of endoscopy treatments should be offered and how these should be used. It aims to improve choice of treatment for adults with Barrett’s oesophagus and improve quality of life and survival for those who cannot have surgery.
-
Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors (CG110)
This guideline covers antenatal care for all pregnant women with complex social factors (particularly alcohol or drug misuse, recent migrant or asylum seeker status, difficulty reading or speaking English, aged under 20, domestic abuse). It offers advice on improving access to care, maintaining contact with antenatal carers, and additional information and support for these women.
-
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
-
Drug misuse in over 16s: psychosocial interventions (CG51)
This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
-
Prostate cancer: diagnosis and management (NG131)
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
-
Obesity: working with local communities (PH42)
This guideline covers how local communities, with support from local organisations and networks, can help prevent people from becoming overweight or obese or help them lose weight. It aims to support sustainable and community-wide action to achieve this.
-
Hepatitis B and C testing: people at risk of infection (PH43)
This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.
-
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
-
Patient experience in adult NHS services: improving the experience of care for people using adult NHS services (CG138)
This guideline covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care.
-
Healthcare-associated infections: prevention and control in primary and community care (CG139)
This guideline covers preventing and controlling healthcare-associated infections in children, young people and adults in primary and community care settings. It provides a blueprint for the infection prevention and control precautions that should be applied by everyone involved in delivering NHS care and treatment.
-
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
-
Neonatal infection (early onset): antibiotics for prevention and treatment (CG149)
This guideline covers preventing infection within 72 hours of birth in healthy babies, treating pregnant women whose baby is at risk, and caring for babies who have a suspected or confirmed infection. It aims to reduce delays in recognising and treating sick babies and prevent unnecessary use of antibiotics.
-
Headaches in over 12s: diagnosis and management (CG150)
This guideline covers advice on the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.
-
Neutropenic sepsis: prevention and management in people with cancer (CG151)
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.
-
Palliative care for adults: strong opioids for pain relief (CG140)
This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by care of dying adults in the last days of life .